{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:33:53Z","timestamp":1794105233982,"version":"4.8.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41573-026-01431-5","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:03:17Z","timestamp":1777291397000},"page":"516-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-5969","authenticated-orcid":false,"given":"Erik S.","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-1145","authenticated-orcid":false,"given":"Agnieszka K.","family":"Witkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-7103","authenticated-orcid":false,"given":"Sheheryar","family":"Kabraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"1431_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/ncb2547","volume":"14","author":"P Nurse","year":"2012","unstructured":"Nurse, P. Finding CDK: linking yeast with humans. Nat. Cell Biol. 14, 776 (2012).","journal-title":"Nat. Cell Biol."},{"key":"1431_CR2","first-page":"73","volume":"96","author":"CJ Sherr","year":"2000","unstructured":"Sherr, C. J. Cell cycle control and cancer. Harvey Lect. 96, 73\u201392 (2000).","journal-title":"Harvey Lect."},{"key":"1431_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","volume":"39","author":"JM Suski","year":"2021","unstructured":"Suski, J. M., Braun, M., Strmiska, V. & Sicinski, P. Targeting cell-cycle machinery in cancer. Cancer Cell 39, 759\u2013778 (2021).","journal-title":"Cancer Cell"},{"key":"1431_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 14, 130\u2013146 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1431_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M Alvarez-Fernandez","year":"2020","unstructured":"Alvarez-Fernandez, M. & Malumbres, M. Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell 37, 514\u2013529 (2020).","journal-title":"Cancer Cell"},{"key":"1431_CR6","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3109\/10428194.2013.783911","volume":"54","author":"JS Blachly","year":"2013","unstructured":"Blachly, J. S. & Byrd, J. C. Emerging drug profile: cyclin-dependent kinase inhibitors. Leukemia lymphoma 54, 2133\u20132143 (2013).","journal-title":"Leukemia lymphoma"},{"key":"1431_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00280-013-2347-y","volume":"73","author":"CC Hofmeister","year":"2014","unstructured":"Hofmeister, C. C. et al. A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother. Pharmacol. 73, 249\u2013257 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1431_CR8","first-page":"1143","volume":"9","author":"H Sedlacek","year":"1996","unstructured":"Sedlacek, H. et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 9, 1143\u20131168 (1996).","journal-title":"Int. J. Oncol."},{"key":"1431_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0968-0004(00)89005-2","volume":"20","author":"CJ Sherr","year":"1995","unstructured":"Sherr, C. J. D-type cyclins. Trends Biochem. Sci. 20, 187\u2013190 (1995).","journal-title":"Trends Biochem. Sci."},{"key":"1431_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMp1612343","volume":"375","author":"CJ Sherr","year":"2016","unstructured":"Sherr, C. J. A new cell-cycle target in cancer - inhibiting cyclin D-dependent kinases 4 and 6. N. Engl. J. Med. 375, 1920\u20131923 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1431_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6, 353\u2013367 (2016).","journal-title":"Cancer Discov."},{"key":"1431_CR12","doi-asserted-by":"publisher","first-page":"6837","DOI":"10.1073\/pnas.92.15.6837","volume":"92","author":"MF Roussel","year":"1995","unstructured":"Roussel, M. F., Theodoras, A. M., Pagano, M. & Sherr, C. J. Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl Acad. Sci. USA 92, 6837\u20136841 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1431_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1073\/pnas.95.3.1091","volume":"95","author":"M Cheng","year":"1998","unstructured":"Cheng, M., Sexl, V., Sherr, C. J. & Roussel, M. F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl Acad. Sci. USA 95, 1091\u20131096 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1431_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0092-8674(91)90101-4","volume":"65","author":"H Matsushime","year":"1991","unstructured":"Matsushime, H., Roussel, M. F., Ashmun, R. A. & Sherr, C. J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65, 701\u2013713 (1991).","journal-title":"Cell"},{"key":"1431_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1101\/gad.7.3.331","volume":"7","author":"J Kato","year":"1993","unstructured":"Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E. & Sherr, C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes. Dev. 7, 331\u2013342 (1993).","journal-title":"Genes. Dev."},{"key":"1431_CR16","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1128\/MCB.15.5.2600","volume":"15","author":"J Lukas","year":"1995","unstructured":"Lukas, J., Bartkova, J., Rohde, M., Strauss, M. & Bartek, J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell Biol. 15, 2600\u20132611 (1995).","journal-title":"Mol. Cell Biol."},{"key":"1431_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc2399","volume":"8","author":"DL Burkhart","year":"2008","unstructured":"Burkhart, D. L. & Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 8, 671\u2013682 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1431_CR18","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1101\/gad.12.15.2245","volume":"12","author":"N Dyson","year":"1998","unstructured":"Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245\u20132262 (1998).","journal-title":"Genes Dev."},{"key":"1431_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.tibs.2022.06.007","volume":"47","author":"M Fischer","year":"2022","unstructured":"Fischer, M., Schade, A. E., Branigan, T. B., Muller, G. A. & DeCaprio, J. A. Coordinating gene expression during the cell cycle. Trends Biochem. Sci. 47, 1009\u20131022 (2022).","journal-title":"Trends Biochem. Sci."},{"key":"1431_CR20","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1101\/gad.12.15.2278","volume":"12","author":"ES Knudsen","year":"1998","unstructured":"Knudsen, E. S., Buckmaster, C., Chen, T. T., Feramisco, J. R. & Wang, J. Y. Inhibition of DNA synthesis by RB: effects on G1\/S transition and S-phase progression. Genes Dev. 12, 2278\u20132292 (1998).","journal-title":"Genes Dev."},{"key":"1431_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.molcel.2019.01.004","volume":"73","author":"I Sanidas","year":"2019","unstructured":"Sanidas, I. et al. A code of mono-phosphorylation modulates the function of RB. Mol. Cell 73, 985\u20131000.e1006 (2019).","journal-title":"Mol. Cell"},{"key":"1431_CR22","first-page":"6587","volume":"62","author":"MP Markey","year":"2002","unstructured":"Markey, M. P. et al. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res. 62, 6587\u20136597 (2002).","journal-title":"Cancer Res."},{"key":"1431_CR23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/436642a","volume":"436","author":"M Collado","year":"2005","unstructured":"Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).","journal-title":"Nature"},{"key":"1431_CR24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/366704a0","volume":"366","author":"M Serrano","year":"1993","unstructured":"Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4. Nature 366, 704\u2013707 (1993).","journal-title":"Nature"},{"key":"1431_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s42003-020-0873-9","volume":"3","author":"ES Knudsen","year":"2020","unstructured":"Knudsen, E. S. et al. Pan-cancer molecular analysis of the RB tumor suppressor pathway. Commun. Biol. 3, 158 (2020).","journal-title":"Commun. Biol."},{"key":"1431_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.trecan.2022.04.006","volume":"8","author":"AK Witkiewicz","year":"2022","unstructured":"Witkiewicz, A. K., Kumarasamy, V., Sanidas, I. & Knudsen, E. S. Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy. Trends Cancer 8, 711\u2013725 (2022).","journal-title":"Trends Cancer"},{"key":"1431_CR27","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel, S., Bergholz, J. S. & Zhao, J. J. Targeting CDK4 and CDK6 in cancer. Nat. Rev. Cancer 22, 356\u2013372 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"1431_CR28","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","volume":"48","author":"PL Toogood","year":"2005","unstructured":"Toogood, P. L. et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6. J. Med. Chem. 48, 2388\u20132406 (2005).","journal-title":"J. Med. Chem."},{"key":"1431_CR29","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427\u20131438 (2004). References 28 and 29 are among the first papers to indicate the preclinical activity of PD0332991 (palbociclib).","journal-title":"Mol. Cancer Ther."},{"key":"1431_CR30","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","volume":"21","author":"T VanArsdale","year":"2015","unstructured":"VanArsdale, T., Boshoff, C., Arndt, K. T. & Abraham, R. T. Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment. Clin. Cancer Res. 21, 2905\u20132910 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR31","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","volume":"26","author":"M Hafner","year":"2019","unstructured":"Hafner, M. et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity. Cell Chem. Biol. 26, 1067\u20131080.e1068 (2019).","journal-title":"Cell Chem. Biol."},{"key":"1431_CR32","doi-asserted-by":"publisher","first-page":"43678","DOI":"10.18632\/oncotarget.18435","volume":"8","author":"ES Knudsen","year":"2017","unstructured":"Knudsen, E. S., Hutcheson, J., Vail, P. & Witkiewicz, A. K. Biological specificity of CDK4\/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget 8, 43678\u201343691 (2017).","journal-title":"Oncotarget"},{"key":"1431_CR33","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1038\/onc.2010.154","volume":"29","author":"JL Dean","year":"2010","unstructured":"Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A. & Knudsen, E. S. Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 29, 4018\u20134032 (2010).","journal-title":"Oncogene"},{"key":"1431_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn, R. S. et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77 (2009). This article provides an initial preclinical report of PD0332991 (palbociclib) efficacy in breast cancer models.","journal-title":"Breast Cancer Res."},{"key":"1431_CR35","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood-2015-11-683581","volume":"127","author":"IZ Uras","year":"2016","unstructured":"Uras, I. Z. et al. Palbociclib treatment of FLT3\u2212ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood 127, 2890\u20132902 (2016).","journal-title":"Blood"},{"key":"1431_CR36","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1016\/j.molcel.2023.10.016","volume":"83","author":"L Crozier","year":"2023","unstructured":"Crozier, L. et al. CDK4\/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence. Mol. Cell 83, 4062\u20134077.e4065 (2023).","journal-title":"Mol. Cell"},{"key":"1431_CR37","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022110764","volume":"41","author":"AR Barr","year":"2022","unstructured":"Barr, A. R. & McClelland, S. E. Cells on lockdown: long-term consequences of CDK4\/6 inhibition. EMBO J. 41, e110764 (2022).","journal-title":"EMBO J."},{"key":"1431_CR38","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-09-4559","volume":"70","author":"K Michaud","year":"2010","unstructured":"Michaud, K. et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70, 3228\u20133238 (2010).","journal-title":"Cancer Res."},{"key":"1431_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.12.094","author":"J Franco","year":"2016","unstructured":"Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K. & Knudsen, E. S. Metabolic reprogramming of pancreatic cancer mediated by CDK4\/6 inhibition elicits unique vulnerabilities. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2015.12.094 (2016).","journal-title":"Cell Rep."},{"key":"1431_CR40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0728","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu, M. T. et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0728 (2016).","journal-title":"Cancer Res."},{"key":"1431_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0650-0","author":"ES Knudsen","year":"2019","unstructured":"Knudsen, E. S. et al. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4\/6 inhibition in patient-derived models of pancreatic cancer. Oncogene https:\/\/doi.org\/10.1038\/s41388-018-0650-0 (2019).","journal-title":"Oncogene"},{"key":"1431_CR42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2275","author":"V Kumarasamy","year":"2020","unstructured":"Kumarasamy, V., Vail, P., Nambiar, R., Witkiewicz, A. K. & Knudsen, E. S. Functional determinants of cell-cycle plasticity and sensitivity to CDK4\/6 inhibition. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2275 (2020).","journal-title":"Cancer Res."},{"key":"1431_CR43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel, S. et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature 548, 471\u2013475 (2017). This paper demonstrates the cancer cell-extrinsic effect of CDK4\/6 inhibitors on immune cells.","journal-title":"Nature"},{"key":"1431_CR44","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1541-7786.MCR-18-0201","volume":"16","author":"AC Chaikovsky","year":"2018","unstructured":"Chaikovsky, A. C. & Sage, J. Beyond the cell cycle: enhancing the immune surveillance of tumors via CDK4\/6 inhibition. Mol. Cancer Res. 16, 1454\u20131457 (2018).","journal-title":"Mol. Cancer Res."},{"key":"1431_CR45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng, J. et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8, 216\u2013233 (2018).","journal-title":"Cancer Discov."},{"key":"1431_CR46","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1126\/science.aas9090","volume":"362","author":"M Ruscetti","year":"2018","unstructured":"Ruscetti, M. et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362, 1416\u20131422 (2018).","journal-title":"Science"},{"key":"1431_CR47","doi-asserted-by":"publisher","first-page":"108944","DOI":"10.1016\/j.celrep.2021.108944","volume":"35","author":"RV Uzhachenko","year":"2021","unstructured":"Uzhachenko, R. V. et al. Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 35, 108944 (2021).","journal-title":"Cell Rep."},{"key":"1431_CR48","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel, S., DeCristo, M. J., McAllister, S. S. & Zhao, J. J. CDK4\/6 Inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 28, 911\u2013925 (2018).","journal-title":"Trends Cell Biol."},{"key":"1431_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/ERC-10-0262","volume":"18","author":"C Thangavel","year":"2011","unstructured":"Thangavel, C. et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr. Relat. Cancer 18, 333\u2013345 (2011).","journal-title":"Endocr. Relat. Cancer"},{"key":"1431_CR50","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-15-0360","volume":"21","author":"SE Wardell","year":"2015","unstructured":"Wardell, S. E. et al. Efficacy of SERD\/SERM hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin. Cancer Res. 21, 5121\u20135130 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR51","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","volume":"21","author":"A DeMichele","year":"2015","unstructured":"DeMichele, A. et al. CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb+\u2009advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin. Cancer Res. 21, 995\u20131001 (2015). This early clinical study illustrates preferential activity of CDK4\/6 inhibitors in specific subtypes of breast cancer.","journal-title":"Clin. Cancer Res."},{"key":"1431_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","volume":"6","author":"A Patnaik","year":"2016","unstructured":"Patnaik, A. et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, other solid. tumors. Cancer Discov. 6, 740\u2013753 (2016). This article reports the results from the phase 1 study of abemaciclib, illustrating efficacy in various tumour types, which supports multiple subsequent clinical trials.","journal-title":"Cancer Discov."},{"key":"1431_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4\/6 inhibitors. Nat. Rev. Clin. Oncol. 13, 417\u2013430 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1431_CR54","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison, L., Loibl, S. & Turner, N. C. The CDK4\/6 inhibitor revolution \u2014 a game-changing era for breast cancer treatment. Nat. Rev. Clin. Oncol. 21, 89\u2013105 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1431_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3206","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3206 (2017). References 55 and 56 report the results from two crucial neoadjuvant trials describing molecular and pathological features of response to CDK4\/6 inhibitors.","journal-title":"Clin. Cancer Res."},{"key":"1431_CR56","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","volume":"26","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz, S. A. et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(\u2009+\u2009)\/HER2(-) breast cancer. Clin. Cancer Res. 26, 566\u2013580 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR57","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon, D. J. et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J. Clin. Oncol. 42, 994\u20131000 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR58","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz, M. P. et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: final overall survival results of MONARCH 3. Ann. Oncol. 35, 718\u2013727 (2024). Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+HER2\u2212 advanced breast cancer: final OS results of MONARCH 3.","journal-title":"Ann. Oncol."},{"key":"1431_CR59","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi, G. N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann. Oncol. 29, 1541\u20131547 (2018).","journal-title":"Ann. Oncol."},{"key":"1431_CR60","doi-asserted-by":"publisher","first-page":"104103","DOI":"10.1016\/j.esmoop.2024.104103","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo, H. S. et al. Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+HER2\u2212 metastatic breast cancer in the US real-world setting. ESMO Open 10, 104103 (2025).","journal-title":"ESMO Open"},{"key":"1431_CR61","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.21.02554","volume":"40","author":"M Gnant","year":"2022","unstructured":"Gnant, M. et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03). J. Clin. Oncol. 40, 282\u2013293 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR62","doi-asserted-by":"publisher","first-page":"S1207","DOI":"10.1016\/j.annonc.2024.08.2251","volume":"35","author":"PA Fasching","year":"2024","unstructured":"Fasching, P. A. et al. LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+HER2\u2212 early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Ann. Oncol. 35, S1207 (2024).","journal-title":"Ann. Oncol."},{"key":"1431_CR63","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi, P. et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J. Clin. Oncol. 42, 987\u2013993 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR64","doi-asserted-by":"publisher","first-page":"e13082","DOI":"10.1200\/JCO.2024.42.16_suppl.e13082","volume":"42","author":"R Orlova","year":"2024","unstructured":"Orlova, R. et al. The analysis of prescribing CDK4\/6 inhibitors for patients with breast cancer in real clinical practice. J. Clin. Oncol. 42, e13082\u2013e13082 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge, G. W. Jr et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116\u2013124 (2020).","journal-title":"JAMA Oncol."},{"key":"1431_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00520-7","volume":"9","author":"A Grinshpun","year":"2023","unstructured":"Grinshpun, A., Tolaney, S. M., Burstein, H. J., Jeselsohn, R. & Mayer, E. L. The dilemma of selecting a first line CDK4\/6 inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer. npj Breast Cancer 9, 15 (2023).","journal-title":"npj Breast Cancer"},{"key":"1431_CR67","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","volume":"636","author":"GS Sonke","year":"2024","unstructured":"Sonke, G. S. et al. Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature 636, 474\u2013480 (2024).","journal-title":"Nature"},{"key":"1431_CR68","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2017.76.9331","volume":"36","author":"N Kornblum","year":"2018","unstructured":"Kornblum, N. et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J. Clin. Oncol. 36, 1556\u20131563 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR69","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer, E. L. et al. PACE: a randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-positive\/human epidermal growth factor receptor-negative metastatic breast cancer. J. Clin. Oncol. 42, 2050\u20132060 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR70","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky, K. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J. Clin. Oncol. 41, 4004\u20134013 (2023). This study demonstrates that sequential use of CDK4\/6 inhibitor is associated with equivalent outcomes to concurrent use with endocrine therapy in patients with HR+ MBC.","journal-title":"J. Clin. Oncol."},{"key":"1431_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00399-w","volume":"8","author":"J Krishnamurthy","year":"2022","unstructured":"Krishnamurthy, J. et al. A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. npj Breast Cancer 8, 35 (2022).","journal-title":"npj Breast Cancer"},{"key":"1431_CR72","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu, Y. S. et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2\u2212 advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin. Cancer Res. 28, 851\u2013859 (2022). This study specifically examines the benefit of first-line ribociclib with endocrine therapy in premenopausal patients with HR+ MBC.","journal-title":"Clin. Cancer Res."},{"key":"1431_CR73","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.24.00144","volume":"42","author":"YS Lu","year":"2024","unstructured":"Lu, Y. S. et al. Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer. J. Clin. Oncol. 42, 2812\u20132821 (2024). This study demonstrates equivalent efficacy of endocrine therapy and ribociclib compared with chemotherapy in patients with HR+ MBC, including those with visceral metastases.","journal-title":"J. Clin. Oncol."},{"key":"1431_CR74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/JCO.18.01624","volume":"37","author":"S Johnston","year":"2019","unstructured":"Johnston, S. et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J. Clin. Oncol. 37, 178\u2013189 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR75","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/JCO.2020.38.15_suppl.505","volume":"38","author":"QJ Khan","year":"2020","unstructured":"Khan, Q. J. et al. Letrozole\u2009+\u2009ribociclib versus letrozole\u2009+\u2009placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial). J. Clin. Oncol. 38, 505\u2013505 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR76","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring, L. M. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1477\u20131486 (2016).","journal-title":"JAMA Oncol."},{"key":"1431_CR77","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","volume":"29","author":"P Cottu","year":"2018","unstructured":"Cottu, P. et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann. Oncol. 29, 2334\u20132340 (2018).","journal-title":"Ann. Oncol."},{"key":"1431_CR78","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1200\/JCO.24.00886","volume":"42","author":"RA Freedman","year":"2024","unstructured":"Freedman, R. A. et al. Optimal adjuvant chemotherapy and targeted therapy for early breast cancer-cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update. J. Clin. Oncol. 42, 2233\u20132235 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR79","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.annonc.2025.10.003","volume":"37","author":"EL Mayer","year":"2026","unstructured":"Mayer, E. L. et al. Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42\/AFT-05\/PrE0109\/BIG-14-13). Ann. Oncol. 37, 271\u2013277 (2026).","journal-title":"Ann. Oncol."},{"key":"1431_CR80","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","volume":"37","author":"S Johnston","year":"2026","unstructured":"Johnston, S. et al. Overall survival with abemaciclib in early breast cancer. Ann. Oncol. 37, 155\u2013165 (2026).","journal-title":"Ann. Oncol."},{"key":"1431_CR81","doi-asserted-by":"publisher","first-page":"105858","DOI":"10.1016\/j.esmoop.2025.105858","volume":"10","author":"J Crown","year":"2025","unstructured":"Crown, J. et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open 10, 105858 (2025).","journal-title":"ESMO Open"},{"key":"1431_CR82","doi-asserted-by":"publisher","first-page":"102944","DOI":"10.1016\/j.ctrv.2025.102944","volume":"136","author":"S Niraula","year":"2025","unstructured":"Niraula, S. Adjuvant CDK4\/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty. Cancer Treat. Rev. 136, 102944 (2025).","journal-title":"Cancer Treat. Rev."},{"key":"1431_CR83","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41401-020-0416-4","volume":"42","author":"XQ Xu","year":"2021","unstructured":"Xu, X. Q. et al. Intrinsic and acquired resistance to CDK4\/6 inhibitors and potential overcoming strategies. Acta Pharmacol. Sin. 42, 171\u2013178 (2021).","journal-title":"Acta Pharmacol. Sin."},{"key":"1431_CR84","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","volume":"3","author":"ES Knudsen","year":"2017","unstructured":"Knudsen, E. S. & Witkiewicz, A. K. The strange case of CDK4\/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer 3, 39\u201355 (2017).","journal-title":"Trends Cancer"},{"key":"1431_CR85","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","volume":"17","author":"GE Konecny","year":"2011","unstructured":"Konecny, G. E. et al. Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer. Clin. Cancer Res. 17, 1591\u20131602 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR86","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.4161\/cc.10.15.16776","volume":"10","author":"AK Witkiewicz","year":"2011","unstructured":"Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P. & Knudsen, E. S. The meaning of p16ink4a expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 10, 2497\u20132503 (2011).","journal-title":"Cell Cycle"},{"key":"1431_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32828-6","volume":"13","author":"M Palafox","year":"2022","unstructured":"Palafox, M. et al. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer. Nat. Commun. 13, 5258 (2022).","journal-title":"Nat. Commun."},{"key":"1431_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0092-4","volume":"4","author":"C Guarducci","year":"2018","unstructured":"Guarducci, C. et al. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. npj Breast Cancer 4, 38 (2018).","journal-title":"npj Breast Cancer"},{"key":"1431_CR89","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-20-2275","volume":"81","author":"V Kumarasamy","year":"2021","unstructured":"Kumarasamy, V., Vail, P., Nambiar, R., Witkiewicz, A. K. & Knudsen, E. S. Functional determinants of cell cycle plasticity and sensitivity to CDK4\/6 inhibition. Cancer Res. 81, 1347\u20131360 (2021).","journal-title":"Cancer Res."},{"key":"1431_CR90","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1390","author":"SA Wander","year":"2020","unstructured":"Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1390 (2020). This study uses matched samples and preclinical studies to define multiple mechanisms associated with disease progression on CDK4\/6 inhibitors.","journal-title":"Cancer Discov."},{"key":"1431_CR91","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa, C. et al. PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3Kalpha inhibitors in breast cancer. Cancer Discov. 10, 72\u201385 (2020).","journal-title":"Cancer Discov."},{"key":"1431_CR92","doi-asserted-by":"publisher","unstructured":"Lin, C. A. et al. ESR1 Y537S and D538G mutations drive resistance to CDK4\/6 inhibitors in estrogen receptor-positive breast cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2307 (2025).","DOI":"10.1158\/1078-0432.CCR-24-2307"},{"key":"1431_CR93","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2653","author":"VM Jansen","year":"2017","unstructured":"Jansen, V. M. et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2653 (2017).","journal-title":"Cancer Res."},{"key":"1431_CR94","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway. Cancer Cell 34, 893\u2013905.e898 (2018). This study combines the use of clinical data and preclinical models to advance HIPPO signalling pathways as important mediators of therapeutic resistance to CDK4\/6 inhibitors.","journal-title":"Cancer Cell"},{"key":"1431_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.379","author":"C Yang","year":"2016","unstructured":"Yang, C. et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene https:\/\/doi.org\/10.1038\/onc.2016.379 (2016).","journal-title":"Oncogene"},{"key":"1431_CR96","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","volume":"12","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors. Cancer Discov. 12, 356\u2013371 (2022).","journal-title":"Cancer Discov."},{"key":"1431_CR97","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41586-021-03445-y","volume":"592","author":"D Simoneschi","year":"2021","unstructured":"Simoneschi, D. et al. CRL4(AMBRA1) is a master regulator of D-type cyclins. Nature 592, 789\u2013793 (2021).","journal-title":"Nature"},{"key":"1431_CR98","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1089\/dna.2021.0659","volume":"40","author":"AC Chaikovsky","year":"2021","unstructured":"Chaikovsky, A. C., Sage, J., Pagano, M. & Simoneschi, D. The long-lost ligase: CRL4(AMBRA1) regulates the stability of D-type cyclins. DNA Cell Biol. 40, 1457\u20131461 (2021).","journal-title":"DNA Cell Biol."},{"key":"1431_CR99","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41586-021-03474-7","volume":"592","author":"AC Chaikovsky","year":"2021","unstructured":"Chaikovsky, A. C. et al. The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D. Nature 592, 794\u2013798 (2021). References 97 and 99 define AMBRA1 as a key cell cycle regulator controlling the stability of cyclin D1.","journal-title":"Nature"},{"key":"1431_CR100","doi-asserted-by":"publisher","first-page":"116140","DOI":"10.1016\/j.celrep.2025.116140","volume":"44","author":"ES Knudsen","year":"2025","unstructured":"Knudsen, E. S., Witkiewicz, A. K., Sanidas, I. & Rubin, S. M. Targeting CDK2 for cancer therapy. Cell Rep. 44, 116140 (2025).","journal-title":"Cell Rep."},{"key":"1431_CR101","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1073\/pnas.1014835108","volume":"108","author":"M Scaltriti","year":"2011","unstructured":"Scaltriti, M. et al. Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl Acad. Sci. USA 108, 3761\u20133766 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1431_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56674-4","volume":"16","author":"V Kumarasamy","year":"2025","unstructured":"Kumarasamy, V. et al. Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nat. Commun. 16, 1476 (2025).","journal-title":"Nat. Commun."},{"key":"1431_CR103","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2244","author":"AP Dommer","year":"2025","unstructured":"Dommer, A. P. et al. Tumor suppressors condition differential responses to the selective CDK2 inhibitor BLU-222. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-2244 (2025).","journal-title":"Cancer Res."},{"key":"1431_CR104","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41586-019-1112-8","volume":"568","author":"A Tomas-Loba","year":"2019","unstructured":"Tomas-Loba, A. et al. p38\u03b3 is essential for cell cycle progression and liver tumorigenesis. Nature 568, 557\u2013560 (2019).","journal-title":"Nature"},{"key":"1431_CR105","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-21-2428","volume":"82","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Golomb, L. & Meyerson, M. Functional genomic analysis of CDK4 and CDK6 gene dependency across human cancer cell lines. Cancer Res. 82, 2171\u20132184 (2022).","journal-title":"Cancer Res."},{"key":"1431_CR106","doi-asserted-by":"publisher","first-page":"110448","DOI":"10.1016\/j.celrep.2022.110448","volume":"38","author":"ES Knudsen","year":"2022","unstructured":"Knudsen, E. S. et al. CDK\/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Rep. 38, 110448 (2022).","journal-title":"Cell Rep."},{"key":"1431_CR107","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin, C. M. et al. Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 83, 141\u2013157 (2023).","journal-title":"Cancer Res."},{"key":"1431_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53837-7","volume":"15","author":"MT Herrera-Abreu","year":"2024","unstructured":"Herrera-Abreu, M. T. et al. Inhibition of GPX4 enhances CDK4\/6 inhibitor and endocrine therapy activity in breast cancer. Nat. Commun. 15, 9550 (2024).","journal-title":"Nat. Commun."},{"key":"1431_CR109","doi-asserted-by":"publisher","first-page":"eabb2210","DOI":"10.1126\/sciadv.abb2210","volume":"6","author":"A Fassl","year":"2020","unstructured":"Fassl, A. et al. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4\/6 inhibition. Sci. Adv. 6, eabb2210 (2020).","journal-title":"Sci. Adv."},{"key":"1431_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01007-z","author":"G Petroni","year":"2025","unstructured":"Petroni, G. et al. IL-17A-secreting \u03b3\u03b4 T cells promote resistance to CDK4\/CDK6 inhibitors in HR+HER2\u2212 breast cancer via CX3CR1+ macrophages. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-025-01007-z (2025).","journal-title":"Nat. Cancer"},{"key":"1431_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering11111084","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Deng, Y., Yang, C. & Naranmandura, H. Double-faced immunological effects of CDK4\/6 inhibitors on cancer treatment: challenges and perspectives. Bioengineering https:\/\/doi.org\/10.3390\/bioengineering11111084 (2024).","journal-title":"Bioengineering"},{"key":"1431_CR112","doi-asserted-by":"publisher","first-page":"216747","DOI":"10.1016\/j.canlet.2024.216747","volume":"588","author":"J Sun","year":"2024","unstructured":"Sun, J. et al. CD63+ cancer-associated fibroblasts confer CDK4\/6 inhibitor resistance to breast cancer cells by exosomal miR-20. Cancer Lett. 588, 216747 (2024).","journal-title":"Cancer Lett."},{"key":"1431_CR113","doi-asserted-by":"publisher","first-page":"101103","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano, A. et al. Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist. Updat. 76, 101103 (2024).","journal-title":"Drug Resist. Updat."},{"key":"1431_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01041-1","volume":"9","author":"NM Kettner","year":"2025","unstructured":"Kettner, N. M. et al. IL-6 predicts CDK4\/6 inhibitor resistance, identifying STAT3 as a target in HR+\/HER2-negative metastatic breast cancer. npj Precis. Oncol. 9, 260 (2025).","journal-title":"npj Precis. Oncol."},{"key":"1431_CR115","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00841","volume":"9","author":"HA Azim","year":"2025","unstructured":"Azim, H. A. et al. Impact of BRCA mutation on treatment outcomes of endocrine therapy \u00b1 CDK4\/6 inhibitors in hormone receptor-positive\/human epidermal growth factor receptor-2-negative breast cancer: a systematic review and meta-analysis. JCO Precis. Oncol. 9, e2400841 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"1431_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10197-0","author":"A Safonov","year":"2026","unstructured":"Safonov, A. et al. Homologous recombination deficiency and hemizygosity drive resistance in breast cancer. Nature https:\/\/doi.org\/10.1038\/s41586-026-10197-0 (2026).","journal-title":"Nature"},{"key":"1431_CR117","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.1016\/j.annonc.2024.08.301","volume":"35","author":"R Scheel","year":"2024","unstructured":"Scheel, R. et al. 353P Clinical outcomes of treatment with CDK4\/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Ann. Oncol. 35, S364 (2024).","journal-title":"Ann. Oncol."},{"key":"1431_CR118","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","volume":"26","author":"SR Vora","year":"2014","unstructured":"Vora, S. R. et al. CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26, 136\u2013149 (2014).","journal-title":"Cancer Cell"},{"key":"1431_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01320-8","volume":"22","author":"NA O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, N. A. et al. Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 22, 89 (2020).","journal-title":"Breast Cancer Res."},{"key":"1431_CR120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501796","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri, K. L. et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2501796 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1431_CR121","doi-asserted-by":"publisher","DOI":"10.1200\/oa-25-00041","author":"G Nader-Marta","year":"2025","unstructured":"Nader-Marta, G., Tolaney, S. M. & Mayer, E. L. Inavolisib-based triplet therapy for PIK3CA-mutated hormone receptor+\/HER2\u2013 breast cancer: clinical implications and practical considerations. JCO Oncol. Adv. https:\/\/doi.org\/10.1200\/oa-25-00041 (2025).","journal-title":"JCO Oncol. Adv."},{"key":"1431_CR122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502929","author":"FC Bidard","year":"2025","unstructured":"Bidard, F. C. et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2502929 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1431_CR123","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa2511218","volume":"394","author":"O Metzger","year":"2026","unstructured":"Metzger, O. et al. Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N. Engl. J. Med. 394, 451\u2013462 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1431_CR124","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clbc.2019.05.010","volume":"19","author":"S Goel","year":"2019","unstructured":"Goel, S. et al. Ribociclib plus trastuzumab in advanced HER2-positive breast cancer: results of a phase 1b\/2 trial. Clin. Breast Cancer 19, 399\u2013404 (2019).","journal-title":"Clin. Breast Cancer"},{"key":"1431_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25422-9","volume":"12","author":"CL Alves","year":"2021","unstructured":"Alves, C. L. et al. Co-targeting CDK4\/6 and AKT with endocrine therapy prevents progression in CDK4\/6 inhibitor and endocrine therapy-resistant breast cancer. Nat. Commun. 12, 5112 (2021).","journal-title":"Nat. Commun."},{"key":"1431_CR126","doi-asserted-by":"publisher","first-page":"2223388","DOI":"10.1080\/15384047.2023.2223388","volume":"24","author":"CL Lee","year":"2023","unstructured":"Lee, C. L. et al. Preclinical evaluation of the CDK4\/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer. Cancer Biol. Ther. 24, 2223388 (2023).","journal-title":"Cancer Biol. Ther."},{"key":"1431_CR127","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/cancers13010006","volume":"13","author":"S La Monica","year":"2020","unstructured":"La Monica, S. et al. Efficacy of the CDK4\/6 dual inhibitor abemaciclib in EGFR-mutated NSCLC cell lines with different resistance mechanisms to osimertinib. Cancers 13, 6 (2020).","journal-title":"Cancers"},{"key":"1431_CR128","doi-asserted-by":"publisher","first-page":"101039","DOI":"10.1016\/j.neo.2024.101039","volume":"57","author":"JF Fu","year":"2024","unstructured":"Fu, J. F., Hsu, C. L. & Hsu, P. C. The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)\/2D\/3D culture models harboring EGFR amplification and CDKN2A\/2B homozygous deletions. Neoplasia 57, 101039 (2024).","journal-title":"Neoplasia"},{"key":"1431_CR129","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2020.03.008","volume":"181","author":"M Ruscetti","year":"2020","unstructured":"Ruscetti, M. et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell 181, 424\u2013441 e421 (2020).","journal-title":"Cell"},{"key":"1431_CR130","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/2159-8290.CD-24-1425","volume":"15","author":"C Broderick","year":"2025","unstructured":"Broderick, C. et al. A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in pancreatic ductal adenocarcinoma. Cancer Discov. 15, 1717\u20131739 (2025).","journal-title":"Cancer Discov."},{"key":"1431_CR131","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1158\/2326-6066.CIR-19-0743","volume":"8","author":"JLF Teh","year":"2020","unstructured":"Teh, J. L. F. et al. Activation of CD8+ T cells contributes to antitumor effects of CDK4\/6 inhibitors plus MEK inhibitors. Cancer Immunol. Res. 8, 1114\u20131121 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"1431_CR132","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321000","author":"ES Knudsen","year":"2020","unstructured":"Knudsen, E. S. et al. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut https:\/\/doi.org\/10.1136\/gutjnl-2020-321000 (2020).","journal-title":"Gut"},{"key":"1431_CR133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3334","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam, F. et al. National cancer institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH). Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3334 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR134","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-18-1161","volume":"19","author":"PJ Roberts","year":"2020","unstructured":"Roberts, P. J., Kumarasamy, V., Witkiewicz, A. K. & Knudsen, E. S. Chemotherapy and CDK4\/6 inhibitors: unexpected bedfellows. Mol. Cancer Ther. 19, 1575\u20131588 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"1431_CR135","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djs002","volume":"104","author":"PJ Roberts","year":"2012","unstructured":"Roberts, P. J. et al. Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy. J. Natl Cancer Inst. 104, 476\u2013487 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"1431_CR136","doi-asserted-by":"publisher","first-page":"29075","DOI":"10.1074\/jbc.M112.365494","volume":"287","author":"JL Dean","year":"2012","unstructured":"Dean, J. L., McClendon, A. K. & Knudsen, E. S. Modification of the DNA damage response by therapeutic CDK4\/6 inhibition. J. Biol. Chem. 287, 29075\u201329087 (2012).","journal-title":"J. Biol. Chem."},{"key":"1431_CR137","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/2767-9764.CRC-22-0072","volume":"2","author":"M Hidalgo","year":"2022","unstructured":"Hidalgo, M. et al. A preclinical and phase Ib study of palbociclib plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas. Cancer Res. Commun. 2, 1326\u20131333 (2022).","journal-title":"Cancer Res. Commun."},{"key":"1431_CR138","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","volume":"37","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero, B. et al. CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell 37, 340\u2013353 e346 (2020).","journal-title":"Cancer Cell"},{"key":"1431_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-1102-1","author":"V Kumarasamy","year":"2019","unstructured":"Kumarasamy, V., Ruiz, A., Nambiar, R., Witkiewicz, A. K. & Knudsen, E. S. Chemotherapy impacts on the cellular response to CDK4\/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Oncogene https:\/\/doi.org\/10.1038\/s41388-019-1102-1 (2019).","journal-title":"Oncogene"},{"key":"1431_CR140","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30609","volume":"70","author":"EA Raetz","year":"2023","unstructured":"Raetz, E. A. et al. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a children\u2019s oncology group study (AINV18P1). Pediatr. Blood Cancer 70, e30609 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"1431_CR141","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-18-0790","volume":"25","author":"AS Clark","year":"2019","unstructured":"Clark, A. S. et al. Combination paclitaxel and palbociclib: results of a phase I trial in advanced breast cancer. Clin. Cancer Res. 25, 2072\u20132079 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR142","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","volume":"30","author":"JM Weiss","year":"2019","unstructured":"Weiss, J. M. et al. Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial. Ann. Oncol. 30, 1613\u20131621 (2019).","journal-title":"Ann. Oncol."},{"key":"1431_CR143","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S1470-2045(19)30616-3","volume":"20","author":"AR Tan","year":"2019","unstructured":"Tan, A. R. et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 20, 1587\u20131601 (2019).","journal-title":"Lancet Oncol."},{"key":"1431_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010430","volume":"13","author":"AC Garrido-Castro","year":"2025","unstructured":"Garrido-Castro, A. C. et al. Phase I study of ribociclib (CDK4\/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. J. Immunother. Cancer 13, e010430 (2025).","journal-title":". Immunother. Cancer"},{"key":"1431_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00482-2","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo, H. S. et al. Abemaciclib in combination with pembrolizumab for HR+, HER2\u2212 metastatic breast cancer: phase 1b study. npj Breast Cancer 8, 118 (2022).","journal-title":"npj Breast Cancer"},{"key":"1431_CR146","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1158\/2159-8290.CD-20-1554","volume":"11","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott, E. J. et al. CDK4\/6 inhibition promotes antitumor immunity through the induction of T-cell memory. Cancer Discov. 11, 2582\u20132601 (2021).","journal-title":"Cancer Discov."},{"key":"1431_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15916","volume":"8","author":"S Vijayaraghavan","year":"2017","unstructured":"Vijayaraghavan, S. et al. CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat. Commun. 8, 15916 (2017).","journal-title":"Nat. Commun."},{"key":"1431_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00722-1","volume":"11","author":"AS Raghavendra","year":"2025","unstructured":"Raghavendra, A. S. et al. Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+\/HER2\u2212 breast cancer. npj Breast Cancer 11, 7 (2025).","journal-title":"npj Breast Cancer"},{"key":"1431_CR149","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/bloodadvances.2022008954","volume":"7","author":"Y Che","year":"2023","unstructured":"Che, Y. et al. Dual targeting of CDK4\/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma. Blood Adv. 7, 3361\u20133365 (2023).","journal-title":"Blood Adv."},{"key":"1431_CR150","doi-asserted-by":"publisher","first-page":"113527","DOI":"10.1016\/j.biopha.2022.113527","volume":"153","author":"A Wang","year":"2022","unstructured":"Wang, A. et al. Palbociclib promotes the antitumor activity of venetoclax plus azacitidine against acute myeloid leukemia. Biomed. Pharmacother. 153, 113527 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1431_CR151","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1158\/1078-0432.CCR-19-1872","volume":"26","author":"JR Whittle","year":"2020","unstructured":"Whittle, J. R. et al. Dual targeting of CDK4\/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer. Clin. Cancer Res. 26, 4120\u20134134 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR152","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2217\/fon-2021-1450","volume":"18","author":"C Muttiah","year":"2022","unstructured":"Muttiah, C., Whittle, J. R., Oakman, C. & Lindeman, G. J. PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. Future Oncol. 18, 1805\u20131816 (2022).","journal-title":"Future Oncol."},{"key":"1431_CR153","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027","volume":"78","author":"S Shu","year":"2020","unstructured":"Shu, S. et al. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer. Mol. Cell 78, 1096\u20131113 e1098 (2020).","journal-title":"Mol. Cell"},{"key":"1431_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16170-3","volume":"11","author":"JY Ge","year":"2020","unstructured":"Ge, J. Y. et al. Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer. Nat. Commun. 11, 2350 (2020).","journal-title":"Nat. Commun."},{"key":"1431_CR155","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","volume":"125","author":"R Scheicher","year":"2015","unstructured":"Scheicher, R. et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 125, 90\u2013101 (2015).","journal-title":"Blood"},{"key":"1431_CR156","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.3324\/haematol.2020.256313","volume":"106","author":"B Maurer","year":"2021","unstructured":"Maurer, B., Brandstoetter, T., Kollmann, S., Sexl, V. & Prchal-Murphy, M. Inducible deletion of CDK4 and CDK6 - deciphering CDK4\/6 inhibitor effects in the hematopoietic system. Haematologica 106, 2624\u20132632 (2021).","journal-title":"Haematologica"},{"key":"1431_CR157","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2025.02.006","volume":"43","author":"CL Palmer","year":"2025","unstructured":"Palmer, C. L. et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell 43, 464\u2013481.e414 (2025). This is, to our knowledge, the first study to describe the specificity and preclinical activity of atirmociclib.","journal-title":"Cancer Cell"},{"key":"1431_CR158","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","volume":"27","author":"PL Palmbos","year":"2021","unstructured":"Palmbos, P. L. et al. A randomized phase II study of androgen deprivation therapy with or without palbociclib in rb-positive metastatic hormone-sensitive prostate cancer. Clin. Cancer Res. 27, 3017\u20133027 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR159","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygyno.2016.07.111","volume":"143","author":"J Kanska","year":"2016","unstructured":"Kanska, J., Zakhour, M., Taylor-Harding, B., Karlan, B. Y. & Wiedemeyer, W. R. Cyclin E as a potential therapeutic target in high grade serous ovarian cancer. Gynecol. Oncol. 143, 152\u2013158 (2016).","journal-title":"Gynecol. Oncol."},{"key":"1431_CR160","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.cell.2023.05.013","volume":"186","author":"M Arora","year":"2023","unstructured":"Arora, M. et al. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell 186, 2628\u20132643.e21 (2023). This paper describes the discovery of dynamic differences related to CDK dependencies.","journal-title":"Cell"},{"key":"1431_CR161","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1158\/1535-7163.MCT-24-0856","volume":"24","author":"A Giddabasappa","year":"2025","unstructured":"Giddabasappa, A. et al. 18F-FLT PET, a noninvasive pharmacodynamic biomarker of tumor cell proliferation, detected differential response to various cyclin-dependent kinase (CDK) inhibitors. Mol. Cancer Ther. 24, 1111\u20131122 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"1431_CR162","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1158\/0008-5472.CAN-24-2360","volume":"85","author":"NC House","year":"2025","unstructured":"House, N. C. et al. Profiling the activity of the potent and highly selective CDK2 inhibitor BLU-222 reveals determinants of response in CCNE1-aberrant ovarian and endometrial tumors. Cancer Res. 85, 1297\u20131309 (2025).","journal-title":"Cancer Res."},{"key":"1431_CR163","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich, C. et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 14, 446\u2013467 (2024).This is, to our knowledge, the first paper to discuss features of the response to CDK2 inhibitors in multiple preclinical models.","journal-title":"Cancer Discov."},{"key":"1431_CR164","doi-asserted-by":"publisher","first-page":"eadv0415","DOI":"10.1126\/scisignal.adv0415","volume":"18","author":"C Sine","year":"2025","unstructured":"Sine, C. et al. p16 expression confers sensitivity to CDK2 inhibitors in cycling E1-driven ovarian cancers. Sci. Signal. 18, eadv0415 (2025). References 102, 103, 160, 162, 163 and 164 represent a collection of studies that further define mechanisms of action and biomarkers of sensitivity to CDK2 inhibitors.","journal-title":"Sci. Signal."},{"key":"1431_CR165","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","volume":"42","author":"R Kudo","year":"2024","unstructured":"Kudo, R. et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell 42, 1919\u20131935.e1919 (2024).","journal-title":"Cancer Cell"},{"key":"1431_CR166","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","volume":"39","author":"K Freeman-Cook","year":"2021","unstructured":"Freeman-Cook, K. et al. Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor. Cancer Cell 39, 1404\u20131421.e1411 (2021).","journal-title":"Cancer Cell"},{"key":"1431_CR167","doi-asserted-by":"publisher","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","volume":"64","author":"KD Freeman-Cook","year":"2021","unstructured":"Freeman-Cook, K. D. et al. Discovery of PF-06873600, a CDK2\/4\/6 inhibitor for the treatment of cancer. J. med. Chem. 64, 9056\u20139077 (2021).","journal-title":"J. med. Chem."},{"key":"1431_CR168","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2740","author":"TA Yap","year":"2025","unstructured":"Yap, T. A. et al. First-in-human phase 1\/2a study of the first-in-class CDK2\/4\/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2740 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR169","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.chembiol.2025.03.006","volume":"32","author":"N Kwiatkowski","year":"2025","unstructured":"Kwiatkowski, N. et al. CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. Cell Chem. Biol. 32, 556\u2013569.e524 (2025).","journal-title":"Cell Chem. Biol."},{"key":"1431_CR170","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41586-025-09433-w","volume":"646","author":"S Singh","year":"2025","unstructured":"Singh, S. et al. Targeting G1\u2013S-checkpoint-compromised cancers with cyclin A\/B RxL inhibitors. Nature 646, 734\u2013745 (2025). References 169 and 170 articulate distinct approaches to target CDK2 in cancer therapy beyond catalytic inhibition.","journal-title":"Nature"},{"key":"1431_CR171","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn, R. S. et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25\u201335 (2015).","journal-title":"Lancet Oncol."},{"key":"1431_CR172","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1158\/1078-0432.CCR-22-2150","volume":"29","author":"AS Clark","year":"2023","unstructured":"Clark, A. S. et al. Phase II study of palbociclib (PD-0332991) in CCND1, 2, or 3 amplification: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) subprotocol Z1B. Clin. Cancer Res. 29, 1477\u20131483 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR173","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/1078-0432.CCR-24-0036","volume":"31","author":"MH O\u2019Hara","year":"2025","unstructured":"O\u2019Hara, M. H. et al. Phase II study of palbociclib in patients with tumors with CDK4 or CDK6 amplification: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1C. Clin. Cancer Res. 31, 56\u201364 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR174","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ijc.34649","volume":"153","author":"LJ Zeverijn","year":"2023","unstructured":"Zeverijn, L. J. et al. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4\/6 pathway alterations in the Dutch DRUP and Australian MoST trials. Int. J. Cancer 153, 1413\u20131422 (2023). The clinical studies reported in references 172\u2013174 illustrate that single gene deregulation is not sufficient to predict sensitivity to CDK4\/6 inhibitors.","journal-title":"Int. J. Cancer"},{"key":"1431_CR175","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","volume":"34","author":"F Andre","year":"2023","unstructured":"Andre, F. et al. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann. Oncol. 34, 1003\u20131014 (2023). This paper provides a comprehensive profile of ctDNA from the MONALEESA clinical trials.","journal-title":"Ann. Oncol."},{"key":"1431_CR176","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.annonc.2024.09.010","volume":"36","author":"F Andre","year":"2025","unstructured":"Andre, F. et al. Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. Ann. Oncol. 36, 54\u201364 (2025).","journal-title":"Ann. Oncol."},{"key":"1431_CR177","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci, F. et al. Genomic characterization of metastatic breast cancers. Nature 569, 560\u2013564 (2019). This article provides comprehensive genetic analyses during metastatic progression of breast cancer.","journal-title":"Nature"},{"key":"1431_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03215-x","volume":"9","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary, B. et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat. Commun. 9, 896 (2018).","journal-title":"Nat. Commun."},{"key":"1431_CR179","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300231","volume":"3","author":"MR Lloyd","year":"2024","unstructured":"Lloyd, M. R. et al. CDK4\/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid. 3, EVIDoa2300231 (2024).","journal-title":"NEJM Evid."},{"key":"1431_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55914-x","volume":"16","author":"Z Kan","year":"2025","unstructured":"Kan, Z. et al. Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4\/6 inhibitors. Nat. Commun. 16, 932 (2025).","journal-title":"Nat. Commun."},{"key":"1431_CR181","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1078-0432.CCR-21-2947","volume":"28","author":"MR Lloyd","year":"2022","unstructured":"Lloyd, M. R., Spring, L. M., Bardia, A. & Wander, S. A. Mechanisms of resistance to CDK4\/6 blockade in advanced hormone receptor-positive, HER2-negative breast cancer and emerging therapeutic opportunities. Clin. Cancer Res. 28, 821\u2013830 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR182","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner, N. C. et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 37, 1169\u20131178 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR183","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2206","author":"A Guerrero-Zotano","year":"2023","unstructured":"Guerrero-Zotano, A. et al. CCNE1 and PLK1 mediates resistance to palbociclib in HR+\/HER2\u2212 metastatic breast cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2206 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00438-0","volume":"7","author":"AK Witkiewicz","year":"2023","unstructured":"Witkiewicz, A. K. et al. Determinants of response to CDK4\/6 inhibitors in the real-world setting. npj Precis. Oncol. 7, 90 (2023).","journal-title":"npj Precis. Oncol."},{"key":"1431_CR185","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3390\/cancers17091482","volume":"17","author":"S Marin-Liebana","year":"2025","unstructured":"Marin-Liebana, S. et al. Gene expression signatures for guiding initial therapy in ER+\/HER2\u2212 early breast cancer. Cancers 17, 1482 (2025).","journal-title":"Cancers"},{"key":"1431_CR186","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/annonc\/mds080","volume":"23","author":"A Prat","year":"2012","unstructured":"Prat, A. et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann. Oncol. 23, 2866\u20132873 (2012). This article reports the association of intrinsic subtypes with response to CDK4\/6 inhibitor-based therapy in MONALEESA clinical trials.","journal-title":"Ann. Oncol."},{"key":"1431_CR187","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1158\/1078-0432.CCR-12-0286","volume":"18","author":"SK Chia","year":"2012","unstructured":"Chia, S. K. et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin. Cancer Res. 18, 4465\u20134472 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR188","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1200\/JCO.20.02977","volume":"39","author":"A Prat","year":"2021","unstructured":"Prat, A. et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J. Clin. Oncol. 39, 1458\u20131467 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR189","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-23-0561","volume":"30","author":"A Prat","year":"2024","unstructured":"Prat, A. et al. Intrinsic subtype and overall survival of patients with advanced HR+\/HER2\u2212 breast cancer treated with ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7. Clin. Cancer Res. 30, 793\u2013802 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR190","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1093\/oncolo\/oyad337","volume":"29","author":"F Schettini","year":"2024","unstructured":"Schettini, F. et al. CDK4\/6-inhibitors versus chemotherapy in advanced HR+\/HER2-negative breast cancer: results and correlative biomarker analyses of the KENDO randomized phase II trial. Oncologist 29, e622\u2013e634 (2024).","journal-title":"Oncologist"},{"key":"1431_CR191","doi-asserted-by":"publisher","first-page":"115219","DOI":"10.1016\/j.ejca.2024.115219","volume":"217","author":"P Tolosa","year":"2025","unstructured":"Tolosa, P. et al. Efficacy outcomes of CDK4\/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive\/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study. Eur. J. Cancer 217, 115219 (2025).","journal-title":"Eur. J. Cancer"},{"key":"1431_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00297-1","volume":"6","author":"Z Zhu","year":"2022","unstructured":"Zhu, Z. et al. Comparative biomarker analysis of PALOMA-2\/3 trials for palbociclib. npj Precis. Oncol. 6, 56 (2022).","journal-title":"npj Precis. Oncol."},{"key":"1431_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03308-0","author":"AK Witkiewicz","year":"2025","unstructured":"Witkiewicz, A. K. et al. Using prognostic signatures and machine learning to identify core features associated with response to CDK4\/6 inhibitor-based therapy in metastatic breast cancer. Oncogene https:\/\/doi.org\/10.1038\/s41388-025-03308-0 (2025).","journal-title":"Oncogene"},{"key":"1431_CR194","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky, K. et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 Inhibition: results from the phase III postMONARCH trial. J. Clin. Oncol. 43, 1101\u20131112 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1431_CR195","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473372","volume":"45","author":"J Teysir","year":"2025","unstructured":"Teysir, J. et al. After a CDK4\/6 inhibitor: state of the art in hormone receptor-positive metastatic breast cancer. Am. Soc. Clin. Oncol. Educ. Book 45, e473372 (2025).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1431_CR196","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00532","volume":"7","author":"JO Brett","year":"2023","unstructured":"Brett, J. O. et al. A gene panel associated with abemaciclib utility in ESR1-mutated breast cancer after prior cyclin-dependent kinase 4\/6-inhibitor progression. JCO Precis. Oncol. 7, e2200532 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"1431_CR197","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-19-3271","volume":"26","author":"A McCartney","year":"2020","unstructured":"McCartney, A. et al. Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial. Clin. Cancer Res. 26, 2131\u20132139 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1431_CR198","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2021.12.030","volume":"164","author":"L Malorni","year":"2022","unstructured":"Malorni, L. et al. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur. J. Cancer 164, 39\u201351 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1431_CR199","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01334-2","volume":"22","author":"L Cabel","year":"2020","unstructured":"Cabel, L. et al. Plasma thymidine kinase 1 activity and outcome of ER+HER2\u2212 metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res. 22, 98 (2020). References 197, 198 and 199 support the utility of TKa as a biomarker of response to CDK4\/6 inhibitors.","journal-title":"Breast Cancer Res."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01431-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:02:25Z","timestamp":1783080145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01431-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":199,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1431"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01431-5","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"25 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.S.K.: sponsored research funding from Bristol Myers Squibb and Blueprint Medicines; consulting activities through Cancer Cell Cycles-LLC. A.K.W.: sponsored research funding from Bristol Myers Squibb, Aleksia Therapeutics and Blueprint Medicines. S.K.: consulting for Daiichi\u2013Sankyo, Gilead and AstraZeneca; speaking engagements with OncLive, Curio-Science and Dava Oncology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}